Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting

Alex Ramírez-Rincón, Carlos E. Builes-Montaño, Jaime A. Hincapié-García, Victor M. Blanco, José F. Botero-Arango

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Background: Type 2 diabetes mellitus (T2DM) is a chronic, highly prevalent disease with a significant impact on health. Appropriate treatment requires effective and timely escalation to achieve metabolic control. To evaluate the effectiveness and safety of IDegLira on adults with T2DM previously treated with oral antidiabetics and/or insulin in a real-life setting. Methods: An observational study in a real-world setting was conducted. Patients were selected from the outpatient clinic of two centers dedicated to specialized diabetes care. Main outcomes were HbA1c, body weight, insulin dose changes, hypoglycemia, and other adverse events. Results: 67 T2DM patients treated with IDegLira were monitored between 3 and 7 months. At the end of foll ow-up, the median change in HbA1c was -1.05% (CI95% -1.45, -0.65), and a decrease in insulin requirement was also observed (mean difference -10 TDD units (CI95% - 17 to -2.5). No treatment discontinuation was reported, hypoglycemia events were reported in 3 patients at the end of follow-up versus 8 patients at baseline. Conclusions: This real-life study shows the effectiveness in glycemic control of IDegLira use in T2DM patients who do not achieve goals with other therapies, with an adequate safety profile. The findings need to be confirmed with evaluation of therapeutic results in larger cohorts.

    Original languageEnglish
    Article number828607
    JournalFrontiers in Endocrinology
    Volume13
    DOIs
    StatePublished - 28 Apr 2022

    Bibliographical note

    Funding Information:
    The medical writing of this article was funded by Novo Nordisk. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

    Publisher Copyright:
    Copyright © 2022 Ramírez-Rincón, Builes-Montaño, Hincapié-García, Blanco and Botero-Arango.

    Keywords

    • IDegLira
    • insulin degludec
    • liraglutide
    • real-world evidence (RWE)
    • type 2 diabetes

    Fingerprint

    Dive into the research topics of 'Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting'. Together they form a unique fingerprint.

    Cite this